Home › Non-Small Cell Lung Cancer › Washington › Kirkland
Non-Small Cell Lung Cancer clinical trials in Kirkland, WA
13 studies for Non-Small Cell Lung Cancer are looking for participants at sites in and around Kirkland (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
RecruitingPhase 3
- Swedish Cancer Institute-Edmonds, Edmonds · 12 mi away
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
RecruitingPhase 1
- Swedish Cancer Institute Medical Oncology, Edmonds · 12 mi away
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
RecruitingPhase 3
- Local Institution - 0515, Edmonds · 12 mi away
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
RecruitingPhase 3
- Swedish Cancer Institute-Edmonds, Edmonds · 12 mi away
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
RecruitingPhase 3
- Swedish Cancer Institute - Edmonds, Edmonds · 12 mi away
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
RecruitingObservational study
- Swedish Cancer Institute-Edmonds, Edmonds · 12 mi away
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
RecruitingPhase 3
- Swedish Cancer Institute - Edmonds, Edmonds · 12 mi away
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
RecruitingPhase 3
- Swedish Cancer Institute, Edmonds · 12 mi away
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
RecruitingPhase 2
- Research Site, Edmonds · 12 mi away
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
RecruitingPhase 2
- Swedish Cancer Institute-Edmonds, Edmonds · 12 mi away
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
RecruitingPhase 2
- Swedish Cancer Institute-Edmonds, Edmonds · 12 mi away
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RecruitingPhase 1
- Swedish Cancer Institute - Edmonds Campus, Edmonds · 12 mi away
- Swedish Cancer Institute Edmonds Campus, Edmonds · 12 mi away
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
RecruitingPhase 2
- FHCC at EvergreenHealth, Kirkland
Non-Small Cell Lung Cancer trials in other cities
- Houston, TX143 studies
- New York City, NY123 studies
- Arlington, VA111 studies
- Nashville, TN97 studies
- Los Angeles, CA92 studies
- Boston, MA87 studies
- St. Louis, MO68 studies
- Baltimore, MD60 studies
- San Antonio, TX60 studies
- Chicago, IL59 studies
- Columbus, OH57 studies
- Seattle, WA55 studies
Other studies in Kirkland
- Parkinson's Disease8 studies
- Colorectal Cancer8 studies
- Lung Cancer8 studies
- Breast Cancer7 studies
- Metastatic Cancer7 studies
- Prostate Cancer7 studies
- Ovarian Cancer6 studies
- Acute Myeloid Leukemia6 studies
- Obesity6 studies
- Overweight6 studies
- Type 2 Diabetes6 studies
- Melanoma6 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.